IntegenX Launches First RapidHIT Human DNA Identification System in Europe

First Rapid DNA Instruments Shipping This Month

IntegenX Launches First RapidHIT Human DNA Identification System in Europe

<0> For IntegenXMaurissa Messier, +1 760-539-7417 </0>

IntegenX Inc., a leading developer of rapid human DNA identification technology, today launched its RapidHIT™ Human DNA Identification System to the European law enforcement and forensic communities at the 6European Academy of Forensic Science (EAFS) Conference in The Hague, The Netherlands. Representatives from IntegenX are on site at the meeting to demonstrate the self-contained desktop system and share data produced by its first users.

The RapidHIT System automates and accelerates the process of producing standardized DNA profiles from cheek swabs and other human samples in about 90 minutes. Rapid DNA analysis is a transformative technology that promises to fundamentally change the way investigations are conducted by enabling law enforcement personnel to quickly and definitively link suspects to crimes while they are still in custody.

“We have spent a great deal of time working closely with the law enforcement, forensic and judicial communities to understand their needs and priorities for DNA-based human identification, and are now confident that we are the partner of choice to help the international community to successfully deploy this important advance in crime solving,” said Stevan Jovanovich, President and Chief Executive Officer of IntegenX. “This is a very exciting time as we introduce the world’s first rapid DNA analysis system to the professionals who will be on the cutting edge of implementing it to identify offenders, clear innocent suspects quickly, and prevent future crimes.”

Numerous international law enforcement and security agencies use DNA-based human identification to make informed decisions regarding the arrest, detention or release of suspects, as well as to analyze crime scene evidence. By integrating a multi-step, multi-system process, rapid DNA technology has the potential to accelerate and expand the use of proven DNA technologies to help the efforts of law enforcement, homeland security, and defense to create safer communities.

The RapidHIT System will be on display at EAFS in exhibit space #58. Technical marketing manager Keith Elliot will describe the instrument and early data from users in “Real-time DNA Using the RapidHIT 200,” Tuesday, August 21 at 11:00 AM, and IntegenX will contribute additional information at the “Mobile DNA Technologies” workshop on Wednesday, August 22 at 9:30 AM.

IntegenX will begin shipping early access RapidHIT systems this month. The company will launch the system to the U.S. market at the 119 Annual International Association of Chiefs of Police Conference and Law Enforcement Education and Technology Exposition in San Diego, California, September 29 – October 3, 2012.

In celebration of this historic milestone in forensics, IntegenX has produced a short video that features leaders in law enforcement discussing the impact of rapid DNA in crime fighting. The video is available for download and distribution at .

IntegenX, headquartered in Pleasanton, California, is a leading developer of rapid human DNA identification technology, next-gen sequencing library preparation, and DNA/RNA ambient temperature stability and storage products. IntegenX technology platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce products for DNA-based human identity testing and forensics, next generation sequencing and biodefense applications. The company’s expertise and extensive intellectual property includes its patented MOVe™ valve technology, patent-pending PrepX™ reagent kits for next generation sequencing library preparation, as well as a portfolio of patented reagents for DNA and RNA preservation including GenTegra™ for stabilization and storage of purified DNA and RNA, and GenPlate for storage of blood samples. For more information, please visit .

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.